Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond

Drug Discovery Today

Volumn 9, Issue 13, 2004, Pages 567-573

  Leeder, J Steven ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

adverse drug reactions; birth defects; developmental; Drug Discovery; immunophenotyping; pediatric; Pharmaceutical Science

Indexed keywords

CITALOPRAM; FLUOXETINE; MERCAPTOPURINE; METHOTREXATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; CONGENITAL MALFORMATION; DNA CONTENT; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TRANSFORMATION; FETUS DEATH; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GROWTH RETARDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; PEDIATRICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PREGNANCY DISORDER; REVIEW; RISK FACTOR; SHOCK;

ABNORMALITIES; ADOLESCENT; CHILD; DRUG DESIGN; DRUG ERUPTIONS; FETAL DISEASES; GENOMICS; HUMANS; INFANT; PHARMACOGENETICS;

EID: 2942532516     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03129-0     Document Type: Review

References (39)

1. Klein T.E., et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J. 1:2001;167-170
2. Farrar H.C., et al. Fetal effects of maternal drug exposure. Annu. Rev. Pharmacol. Toxicol. 31:1991;525-547
3. Wells P.G., et al. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31:1996;1-40
4. Poirier M.C., et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J. Acquir. Immune Defic. Syndr. 33:2003;175-183
5. Barret B., et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 17:2003;1769-1785
6. Boonstra H. Human embryo and fetal research: Medical support and political controversy. The Guttmacher Report on Public Policy. 4:2001;3-5
7. Leeder J.S. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr. Ther. Res. 62:2001;900-912
8. Hines R.N., et al. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300:2002;355-360
9. McCarver D.G., et al. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300:2002;361-366
10. Cohen L.S., et al. Birth outcomes following prenatal exposure to fluoxetine. Biol. Psychiatry. 48:2000;996-1000
11. Laine K., et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry. 60:2003;720-726
12. Isbister G.K., et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch. Dis. Child. Fetal Neonatal Ed. 85:2001;F145
13. Belay E.D., et al. Reye's syndrome in the United States from 1981 through 1997. N. Engl. J. Med. 340:1999;1377-1382
14. Bryant A.E., et al. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 46:1996;465-469
15. Messenheimer J.A. Rash in adult and pediatric patients treated with lamotrigine. Can. J. Neurol. Sci. 25:1998;S14-S18
16. Guberman A.H., et al. Lamotrigine-induced rash: Risk/benefit considerations in adults and children. Epilepsia. 40:1999;985-991
17. Leeder J.S. Pharmacogenetics and pharmacogenomics. Pediatr. Clin. North Am. 48:2001;765-781
18. Takahashi H., et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther. 68:2000;541-555
19. Relling M.V., et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 354:1999;34-39
20. Relling M.V., et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 12:1998;346-352
21. Relling M.V., et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 101:2003;3862-3867
22. Yeoh E-J., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1:2002;133-143
23. Brand P.L. Inhaled corticosteroids reduce growth. Or do they? Eur. Respir. J. 17:2001;287-294
24. Wright A.L., et al. Lessons from long-term cohort studies. Childhood asthma. Eur. Respir. J. Suppl. 27:1998;17S-22S
25. Cheok M.H., et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. 34:2003;85-90
26. Frantz S. Antidepressant use in children questioned. Nat. Rev. Drug Discov. 2:2003;939
27. Neel J.V. Diabetes mellitus: a 'thrifty' genotype rendered detrimental by 'progress'? Am. J. Hum. Genet. 14:1962;353-362
28. Hales C.N., et al. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 35:1992;595-601
29. Barker D.J.P. Mothers, Babies and Disease in Later Life. British Medical Journal. 1994
30. Gillman M.W., et al. The fetal origins of adult disease: from sceptic to convert. Paed. Perinatal Epidemiol. 14:2000;192-193
31. Holmäng A. Perinatal origin of adult disease. Scand. Cardiovasc. J. 35:2001;178-185
32. Machón R.A., et al. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry. 54:1997;322-328
33. Langley-Evans S.C., et al. Intrauterine programming of hypertension: the role of the renin-angiotensin system. Biochem. Soc. Trans. 27:1999;88-93
34. Newnham J.P. Is prenatal glucocorticoid administration another origin of adult disease? Clin. Exp. Pharmacol. Physiol. 28:2001;957-961
35. Sartori C., et al. Augmented vasoreactivity in adult life associated with perinatal vascular insult. Lancet. 353:1999;2205-2207
36. Nebert D.W., et al. Pharmacogenomics and 'individualized drug therapy'. Am. J. Pharmacogenomics. 3:2003;361-370
37. 2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100:1997;3184-3188
38. Shao Y., et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am. J. Hum. Genet. 72:2003;539-548
39. Freimer N., et al. The human phenome project. Nat. Genet. 34:2003;15-21